首页> 外国专利> RISK EVALUATION AND MANAGEMENT STRATEGY INVOLVING PATIENT FOLLOW-UPS RELATING TO A COMPLEMENT INHIBITOR

RISK EVALUATION AND MANAGEMENT STRATEGY INVOLVING PATIENT FOLLOW-UPS RELATING TO A COMPLEMENT INHIBITOR

机译:涉及补足抑制剂的患者随访的风险评估和管理策略

摘要

This invention provides, inter alia, a complement-inhibitor-based treatment plan coupled with a risk evaluation and management strategy ("REMS") and a safety support program ("SSP") for reinforcing the REMS. The REMS and SPP are implemented using one or more computer devices with software tools programmed to enforce conditions of the REMS and/or prompt follow-ups by registered nurses enrolled in the SSP. The software tool(s) determines whether a prescriber requesting the complement inhibitor has agreed to abide by the REMS, and can prompt a provider of the complement inhibitor to provide updated educational materials to the prescriber at predetermined times or intervals, to monitor the prescriber for compliance with the REMS, and/or to monitor patients for signs of adverse events. Using exemplary embodiments described herein, a risk of adverse events (especially, but not limited to, meningococcal infections) can be managed and an incidence of the adverse events can be reduced.
机译:本发明尤其提供基于补体抑制剂的治疗计划,并结合风险评估和管理策略(“ REMS”)和用于增强REMS的安全支持程序(“ SSP”)。 REMS和SPP使用一台或多台计算机设备来实现,其软件工具被编程为强制执行REMS的条件和/或由SSP中注册的注册护士进行快速跟进。该软件工具确定请求补体抑制剂的处方者是否已同意遵守REMS,并且可以提示补体抑制剂的提供者以预定的时间或间隔向处方者提供更新的教育材料,以监测处方者的情况。符合REMS,和/或监视患者是否有不良反应的迹象。使用本文所述的示例性实施方案,可以控制不良事件的风险(特别是但不限于脑膜炎球菌感染),并且可以减少不良事件的发生率。

著录项

  • 公开/公告号WO2016081314A1

    专利类型

  • 公开/公告日2016-05-26

    原文格式PDF

  • 申请/专利权人 ALEXION PHARMACEUTICALS INC.;

    申请/专利号WO2015US60677

  • 发明设计人 BELL LEONARD;BEDROSIAN CAMILLE;

    申请日2015-11-13

  • 分类号G06Q10;

  • 国家 WO

  • 入库时间 2022-08-21 14:17:43

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号